AS1411 Aptamer/Hyaluronic Acid-Bifunctionalized Microemulsion Co-Loading Shikonin and Docetaxel for Enhanced Antiglioma Therapy

Wang, Hong; Zhu, Zhihan; Zhang, Guilong; Lin, Fei-Xiang; Liu, Yong; Zhang, Yu; Feng, Jia; Chen, Wanghao; Meng, Qiang; Chen, Lukui

doi:10.1016/j.xphs.2019.08.017

Cited by 33 publications

(28 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 We have previously fabricated an AS1411-modified microemulsion coloaded with docetaxel (DTX) and shikonin (SKN) (AS1411/DTX&SKN-M) for glioma delivery. 14 As reported in our study, DTX is a type of broadspectrum anti-tumor drug but incapable of crossing the BBB. SKN is able to reduce cancer stem cells (CSCs) population of gliomas and strength the anti-glioma efficacy of some chemotherapeutic agents.…”

Section: Introductionsupporting

confidence: 54%

A Magnetic T7 Peptide&AS1411 Aptamer-Modified Microemulsion for Triple Glioma-Targeted Delivery of Shikonin and Docetaxel

Wang

Chen

Guo-juan

et al. 2021

Journal of Pharmaceutical Sciences

Self Cite

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 54%

A Magnetic T7 Peptide&AS1411 Aptamer-Modified Microemulsion for Triple Glioma-Targeted Delivery of Shikonin and Docetaxel

Wang

Chen

Guo-juan

et al. 2021

Journal of Pharmaceutical Sciences

Self Cite

View full text Add to dashboard Cite

“…This nanomaterial can be used for in vivo and in vitro imaging. Based on the ability of AS1411 aptamer/hyaluronic acid bifunctional microlatex to co-contain paclitaxel and docetaxel (AS1411/SKN&DTX-M), Wang [ 147 ] penetrate the blood–brain barrier and inhibit the growth of in-situ gliomas by targeting CD44/nuclide overexpression in gliomas in 2019. Figure 11 B shows A schematic synthesis of A polyethylene glycolated polyamide-amine dendrimer.…”

Section: Application Of As1411 Modified Nanomaterialsmentioning

confidence: 99%

Progress in cancer drug delivery based on AS1411 oriented nanomaterials

Tong

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

Targeted cancer therapy has become one of the most important medical methods because of the spreading and metastatic nature of cancer. Based on the introduction of AS1411 and its four-chain structure, this paper reviews the research progress in cancer detection and drug delivery systems by modifying AS1411 aptamers based on graphene, mesoporous silica, silver and gold. The application of AS1411 in cancer treatment and drug delivery and the use of AS1411 as a targeting agent for the detection of cancer markers such as nucleoli were summarized from three aspects of active targeting, passive targeting and targeted nucleic acid apharmers. Although AS1411 has been withdrawn from clinical trials, the research surrounding its structural optimization is still very popular. Further progress has been made in the modification of nanoparticles loaded with TCM extracts by AS1411. Graphical Abstract

show abstract

“…Recently, it has been reported that SKN and DTX co-loaded nanoemulsion bifunctionalized with AS1411 aptamer, and HA penetrated the BBB, inhibited tumor growth, and prolonged the survival period in vivo. The nanoemulsion was accurately delivered to the glioma region through the high affinity between HA and CD44 receptor, AS1411 and nucleolin, and SKN reduced the population of CSCs [ 132 ]. Another study showed that IGU loaded PLGA NPs (IGU-PLGA-NPs) were able to improve therapeutic outcomes in glioma, glioma stem-like cells, and temozolomide resistant glioma cells.…”

Section: Application and Clinical Trials Of Nanocarrier-based Thermentioning

confidence: 99%

Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies

Wei

Lau

2020

Cancers

View full text Add to dashboard Cite

Conventional chemotherapy is still an important option of cancer treatment, but it has poor cell selectivity, severe side effects, and drug resistance. Utilizing nanoparticles (NPs) to improve the therapeutic effect of chemotherapeutic drugs has been highlighted in recent years. Nanotechnology dramatically changed the face of oncology by high loading capacity, less toxicity, targeted delivery of drugs, increased uptake to target sites, and optimized pharmacokinetic patterns of traditional drugs. At present, research is being envisaged in the field of novel nano-pharmaceutical design, such as liposome, polymer NPs, bio-NPs, and inorganic NPs, so as to make chemotherapy effective and long-lasting. Till now, a number of studies have been conducted using a wide range of nanocarriers for the treatment of solid tumors including lung, breast, pancreas, brain, and liver. To provide a reference for the further application of chemodrug-loaded nanoformulations, this review gives an overview of the recent development of nanocarriers, and the updated status of their use in the treatment of several solid tumors.

show abstract

AS1411 Aptamer/Hyaluronic Acid-Bifunctionalized Microemulsion Co-Loading Shikonin and Docetaxel for Enhanced Antiglioma Therapy

Cited by 33 publications

References 33 publications

A Magnetic T7 Peptide&AS1411 Aptamer-Modified Microemulsion for Triple Glioma-Targeted Delivery of Shikonin and Docetaxel

A Magnetic T7 Peptide&AS1411 Aptamer-Modified Microemulsion for Triple Glioma-Targeted Delivery of Shikonin and Docetaxel

Progress in cancer drug delivery based on AS1411 oriented nanomaterials

Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies

Contact Info

Product

Resources

About